Clinical trials: Psychotic Disorder
Schizophrenia, Bipolar Disorder
Individualizing Incentives for Alcohol in the Severely Mentally Ill
The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol…
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
- Trial name
- NCT03481049
- Testing
- Usual CM, High-Magnitude CM, Shaping CM
- Where
- 2 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Washington State University
Schizophrenia
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
This is a Phase 2, randomized, double-blinded, placebo-controlled, inpatient study to examine the efficacy, safety, and tolerability profile of KarXT in adult subjects diagnosed with DSM-5 schizophrenia who are in an acute…
- Trial name
- EMERGENT-1 (NCT03697252)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 12 sites in United States
- Volunteers
- 182 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
- Trial name
- NCT01854944
- Testing
- Brexpiprazole 1mg to 4mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Auditory Hallucination
Boost rTMS for Auditory Verbal Hallucinations
This is a randomized, placebo controlled, double-blind clinical trial. The investigators aim to examine the safety and efficacy of repeated transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal…
- Trial name
- NCT03544333
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northwell Health
Tobacco Use Disorder, Schizophrenia
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related…
- Trial name
- NCT01213524
- Testing
- sensorimotor replacement, 42 mg transdermal nicotine replacement, usual brand smoking
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Brown University
Schizophrenia
Repetitive Transcranial Magnetic Stimulation for "Voices"
OBJECTIVES: I. Determine the effect of repetitive transcranial magnetic stimulation on treatment refractory auditory hallucinations of patients with schizophrenia.
- Trial name
- NCT00004980
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Schizophrenia
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who…
- Trial name
- NCT01515423
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 174 sites in United States, Argentina and 24 more
- Volunteers
- 1,429 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia.
- Trial name
- NCT00963924
- Testing
- D-cycloserine, Cognitive Remediation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
The purpose of this study is to determine whether cognitive training exercises can improve cognitive functioning in young patients with recent-onset psychosis who are being treated in community mental health settings using the…
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- Mini-COTES (NCT03079024)
- Testing
- Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Schizophrenia
Nicotine Effects on Endophenotypes of Schizophrenia
The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal…
- Trial name
- NCT01315002
- Testing
- Transdermal nicotine patch
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Schizophrenia
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
The purpose of this study is to determine whether add-on luvadaxistat is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).
- Trial name
- NCT03382639
- Testing
- Luvadaxistat
- Where
- 54 sites in United States, Bulgaria and 6 more
- Volunteers
- 256 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
- Trial name
- SPECTRUM (NCT00640601)
- Testing
- Quetiapine Fumarate Extended- Release
- Where
- 36 sites in Australia, Canada and 2 more
- Volunteers
- 331 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Healthy
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in…
- Trial name
- NCT00698022
- Testing
- Risperidone, Mifepristone
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Psychosis
mHealth for Psychosis Help-seeking
The proposed study research project aims to develop and test a mobile health intervention designed to improve the wellness of young people at risk for psychosis and facilitate users' engagement with treatment and thus reduce…
- Trial name
- NCT05905601
- Testing
- NORTH "Full", NORTH "Lite"
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Smoking Cessation, Schizophrenia
Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into three arms of treatment for smoking…
- Trial name
- NCT02676375
- Testing
- Combination Bupropion + NRTs, Extended Treatment, Home Visits & Calls
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Brentwood Biomedical Research Institute
Schizophrenia
Multicenter, Open-label, Safety and Tolerability Study
This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis.
- Trial name
- STEP 210 (NCT01649557)
- Testing
- OPC-34712
- Where
- 68 sites in United States, Bulgaria and 10 more
- Volunteers
- 244 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)
The purpose of this study is to explore the relationship between achieving symptomatic remission status by means of the 8 items of Positive and Negative Syndrome Scale (PANSS), and personal and social functioning by means of the…
- Trial name
- NCT01577186
- Testing
- Paliperidone ER
- Volunteers
- 480 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL…
- Trial name
- NCT02462473
- Testing
- Aripiprazole, Olanzapine, Paliperidone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Janssen Research & Development, LLC